HSBC Holdings’s Radiopharm Theranostics RADX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$33.9K Sell
22,483
-39,705
-64% -$111K ﹤0.01% 2846
2026
Q2
$254K Buy
62,188
+816
+1% +$3.63K ﹤0.01% 2596
2026
Q1
$265K Sell
61,372
-130,252
-68% -$637K ﹤0.01% 2504
2025
Q4
$1.01M Buy
+191,624
New +$1.02M ﹤0.01% 1942

Other funds holding RADX

HSBC Holdings's RADX Position: Q3 2026 in Review

HSBC Holdings reduced its Radiopharm Theranostics (RADX) stake by 64% in Q3 2026, selling an estimated $111K and leaving 22,483 shares worth $33.9K. The position accounts for ﹤0.01% of the portfolio, ranked #2846.

HSBC Holdings first reported a position in RADX in Q4 2025 and has held it in 4 quarters since. The position peaked at $1.01M in Q4 2025. 8 funds tracked by Wall St. Rank hold RADX as of Q3 2026.

  • HSBC Holdings held 22,483 shares of Radiopharm Theranostics worth $33.9K as of Q3 2026.
  • HSBC Holdings sold 39,705 Radiopharm Theranostics shares in Q3 2026, an estimated $111K.
  • Radiopharm Theranostics made up ﹤0.01% of HSBC Holdings's portfolio in Q3 2026, its #2846 holding.
  • HSBC Holdings first reported a position in Radiopharm Theranostics in Q4 2025 and has held it in 4 quarters since.
  • HSBC Holdings's Radiopharm Theranostics position peaked at $1.01M in Q4 2025.
  • 8 funds tracked by Wall St. Rank held Radiopharm Theranostics as of Q3 2026.

Based on HSBC Holdings's 13F filing for Q3 2026, filed 16 Nov 2026.